Ipamorelin can trigger a growth hormone pulse. That has been measured in healthy men, while most claims about muscle, fat loss and brain health come from other kinds of evidence. The clearest patient trial tested recovery of bowel function after surgery. It missed its main target.
Ipamorelin activates the ghrelin receptor. CJC-1295 works through another receptor, so the two peptides need separate evidence. Ipamorelin studies range from a short human hormone experiment to rat work on bone, muscle and gut movement.
The receptor is GHSR1a
The growth hormone secretagogue receptor, usually written GHSR1a, is also called the ghrelin receptor. Ghrelin is a hormone involved in appetite, gut activity and growth hormone signaling. Ipamorelin activates this receptor pathway. GHSR1a is not the growth hormone receptor, a unique fat receptor, or a receptor invented for ipamorelin. The pituitary gland responds to several signals, and stimulation of one route does not predict every downstream health effect.
The original pharmacology paper used rat pituitary cells, anesthetized rats and conscious pigs. Ipamorelin released growth hormone in these preparations. Antagonist experiments distinguished a growth hormone secretagogue route from the separate growth hormone releasing hormone route. In pigs, the investigators measured several hormones and found ipamorelin more selective for growth hormone release than the related peptides they tested, especially with respect to cortisol and ACTH (Original ipamorelin receptor study: https://pubmed.ncbi.nlm.nih.gov/9849822/).
In that paper, selective describes the hormones measured at the doses tested. The result cannot rule out other effects or establish safety for a person using a product of uncertain quality.
Human study one: a hormone response
Researchers next studied healthy men given ipamorelin by a short intravenous infusion. Five dose groups included eight men each. Blood samples tracked ipamorelin and growth hormone over time. Growth hormone rose in a pulse that peaked about 40 minutes after infusion began, while the estimated terminal half-life of the peptide was about two hours (Human pharmacokinetic and hormone study: https://pubmed.ncbi.nlm.nih.gov/10496658/).
The experiment confirms a short growth hormone response in healthy men. It did not track strength, sleep, fat loss, fracture healing or long-term health. The sample was small, involved healthy male volunteers, and observed a short time window. The intravenous study also does not validate a different dose, route or product sold outside a trial.
Growth hormone and insulin-like growth factor 1, or IGF-1, participate in many processes. More of either blood marker is not automatically a benefit. The meaningful endpoint depends on the claim. A muscle claim needs measurements of useful strength and function. A recovery claim needs recovery outcomes. A cognition claim needs validated measures of thinking or daily life. This early study measured none of those.
Human study two: bowel recovery after surgery
The best published test of a possible patient benefit focused on postoperative ileus, a temporary slowdown of the gut after surgery. Ghrelin receptor activity offered a reason to test whether ipamorelin could get the bowel moving and help patients tolerate food sooner. In a multicenter, double-blind, placebo-controlled phase 2 study, 117 adults undergoing small or large bowel resection were enrolled. The safety and modified intention-to-treat analyses included 114 people. Participants received ipamorelin or placebo twice daily for up to seven days or until hospital discharge (Ipamorelin bowel-surgery trial: https://pubmed.ncbi.nlm.nih.gov/25331030/).
Investigators chose time from the first treatment until a standardized solid meal could be tolerated as the key efficacy outcome. The median was 25.3 hours with ipamorelin and 32.6 hours with placebo. A seven-hour numerical difference sounds promising, but the reported p value was 0.15. The study did not demonstrate a statistically convincing benefit on its main outcome, and the secondary efficacy analyses were also not significantly different. Adverse events were common in both groups in this postoperative setting.
A larger trial might produce a clearer estimate, especially in a more uniform group of surgical patients. With the present data, there is no demonstrated reliable improvement in bowel recovery. A hormone pulse in healthy men cannot override a clinical trial that asked the patient question directly.
Bone growth in rats: larger is not always stronger
Several animal papers explored growth and bone. Adult female rats given repeated ipamorelin injections over 15 days had a dose-related increase in longitudinal tibial growth and body weight. Total blood IGF-1 did not rise significantly in that experiment (Rat tibial-growth experiment: https://pubmed.ncbi.nlm.nih.gov/10373343/). The outcome was lengthwise growth of a rat leg bone, not healing of a broken bone in a person.
In a 12-week experiment, young adult female rats received ipamorelin, another secretagogue, growth hormone or vehicle. Some measures of bone mineral content rose with the growing bones and body size. Volumetric bone mineral density did not improve in the same way (Rat bone-mineral experiment: https://pubmed.ncbi.nlm.nih.gov/10828840/). The difference between mineral content and density matters. More mineral in a bigger bone does not by itself show better bone quality or fewer fractures.
Neither trial measured fracture prevention, mobility, pain or outcomes in older adults. They are useful for understanding how a growth hormone secretagogue affects a developing animal model, but they cannot be repackaged as evidence that ipamorelin treats human osteoporosis.
Muscle and catabolism models
Researchers also asked whether ipamorelin could oppose some consequences of glucocorticoid exposure in rats. Glucocorticoids can promote muscle and bone loss, creating a specific experimental catabolic state. In one three-month study, selected muscle-force and bone-formation measures improved when ipamorelin accompanied the glucocorticoid compared with the glucocorticoid alone (Steroid-treated rat muscle and bone study: https://pubmed.ncbi.nlm.nih.gov/11735244/). Another rat experiment examined nitrogen balance and urea handling under steroid-induced catabolism (Steroid-treated rat nitrogen study: https://pubmed.ncbi.nlm.nih.gov/19231263/).
These studies are relevant to questions about wasting, but they are not trials of exercise recovery or muscle gain in healthy adults. Body weight, muscle force in a rat, and nitrogen handling are different endpoints. Even if a laboratory outcome changes, a later human study must determine whether patients function better and whether harms outweigh gains.
Gut studies that led to the human test
In a rat model of postoperative ileus, researchers tested whether ipamorelin could restore bowel activity after surgery. Repeated treatment improved some measures of stool output, food intake and weight over 48 hours. A single dose changed time to first stool but did not improve every measured outcome (Rat postoperative-ileus study: https://pubmed.ncbi.nlm.nih.gov/19289567/). A separate rodent experiment reported faster gastric emptying, and work on isolated stomach tissue pointed toward a ghrelin receptor and cholinergic nerve pathway (Rat gastric-motility study: https://pubmed.ncbi.nlm.nih.gov/27186127/).
The rat findings gave researchers a reason to try ipamorelin after human bowel surgery. The later patient trial failed to confirm a clear benefit. Claims about postoperative recovery need to include that result.
A fat-loss claim meets an awkward mouse result
Ipamorelin is sometimes promoted for reducing body fat, yet one original mouse experiment found a different pattern. Researchers treated mice with and without normal growth hormone function with ipamorelin or growth hormone. Ipamorelin increased fat-pad weight relative to body weight in two mouse genotypes. In growth-hormone-intact mice, growth hormone secretagogues increased relative body fat, food intake and leptin over two weeks (Mouse adiposity study: https://pubmed.ncbi.nlm.nih.gov/11162489/). The experiment cannot predict a human weight outcome, but it directly contradicts the easy assumption that a growth hormone pulse must lead to fat loss.
Other animal findings and open questions
Longer exposure in young female rats changed growth hormone producing pituitary cells when investigators later tested tissue outside the animal (Rat pituitary study: https://pubmed.ncbi.nlm.nih.gov/12168778/). An isolated rat pancreas experiment reported increased insulin release (Rat pancreas study: https://pubmed.ncbi.nlm.nih.gov/15665799/). The pituitary and pancreas results raise questions about effects beyond a single growth hormone pulse. Human studies have yet to establish what those changes would mean for health.
In a ferret model of cisplatin exposure, ipamorelin reduced weight loss. The main anti-nausea result applied to a different ghrelin receptor agonist in the same experiment (Ferret study: https://pubmed.ncbi.nlm.nih.gov/39043357/). A result under a toxic drug challenge should not be recast as evidence that ipamorelin helps a healthy person manage body weight.
What about the brain, GABA and Selank?
GHSR1a occurs in parts of the nervous system. Rat brain-slice work showed that ghrelin could change a GABA-related circuit involved in regulating vasopressin neurons (Ghrelin and GABA circuit study: https://pubmed.ncbi.nlm.nih.gov/24790191/). Other rat and mouse neuronal experiments investigated how ghrelin receptor signaling affects calcium channels and GABA release (Neuronal receptor study: https://pubmed.ncbi.nlm.nih.gov/26283199/). These are mechanistic studies of ghrelin or receptor manipulation. They did not give ipamorelin to people with anxiety, attention problems or neurologic disease.
Selank is a separate peptide. Rat studies of Selank reported changes in GABA-related gene expression and, in an ethanol-exposure model, measurements involving brain-derived neurotrophic factor, or BDNF (Selank gene study: https://pubmed.ncbi.nlm.nih.gov/26924987/; Selank BDNF study: https://pubmed.ncbi.nlm.nih.gov/31625062/). Those results cannot be assigned to ipamorelin because both substances are called peptides. Our Selank evidence article covers its distinct record. Ipamorelin has not been shown to work through a unique Selank-like GABA or BDNF treatment pathway.
Safety, product quality and the next useful study
The US Food and Drug Administration identifies potential immune reactions and impurity problems for compounded ipamorelin acetate, and says it lacks adequate safety information for some injectable routes (FDA compounding safety information: https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks). Serious events associated with intravenous use have been reported, although an association is not proof that ipamorelin caused each event. A seven-day hospital trial and a small healthy-volunteer experiment cannot establish safety for repeated personal use over months or years.
The next trials need a verified product and patients with a defined condition. They should compare it with placebo, measure how people recover or function, and follow adverse effects beyond a few days. The existing record supports ipamorelin's ability to stimulate growth hormone. It does not establish the advertised benefits for fat loss, muscle gain, longevity or brain health. The BPC-157 evidence review offers another example of why a peptide's animal results cannot substitute for a successful patient trial.
